SCHEMBL179040

SCHEMBL179040

CC(C)c1ccc(-c2nc3ccccc3c(=O)[nH]2)cc1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TNKS O95271 14/20 0.71
TNKS2 Q9H2K2 12/20 0.71
PARP1 P09874 6/20 0.71
GUSB P08236 7/20 0.71
PARP2 Q9UGN5 3/20 0.71
CYP1A1 P04798 1/20 0.67
CYP1B1 Q16678 1/20 0.67
NPC1 O15118 3/20 0.66
RAB9A P51151 3/20 0.66
MAPT P10636 2/20 0.66
KDM4E B2RXH2 2/20 0.66
CASP3 P42574 1/20 0.66
SENP7 Q9BQF6 1/20 0.66
SENP6 Q9GZR1 1/20 0.66
ALDH1A1 P00352 1/20 0.64
HPGD P15428 1/20 0.64
ALOX15 P16050 1/20 0.64
HSD17B10 Q99714 1/20 0.64
APOBEC3G Q9HC16 1/20 0.64
WNT3A P56704 1/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6885282 0.87 TNKS (0.93) TNKSTNKS2PARP1GUSBPARP2
SCHEMBL6124189 0.84 TNKS (0.93) TNKSTNKS2PARP1GUSBPARP2
SCHEMBL258433 0.84 TNKS (1.00) TNKSTNKS2PARP1GUSBPARP2
SCHEMBL29592833 0.84 TNKS (1.00) TNKSTNKS2PARP1GUSBPARP2
SCHEMBL8618931 0.83 TNKS (1.00) TNKSTNKS2PARP1GUSBPARP2
SCHEMBL15775207 0.83 TNKS (1.00) TNKSTNKS2PARP1GUSBPARP2
SCHEMBL7765127 0.83 TNKS (1.00) TNKSTNKS2PARP1GUSBPARP2
SCHEMBL29764113 0.83 TNKS (1.00) TNKSTNKS2PARP1GUSBPARP2
Hydrochloric Acid SCHEMBL31529601 0.82 TNKS (0.96) TNKSTNKS2PARP1GUSBPARP2
SCHEMBL16965507 0.81 TNKS (0.69) TNKSTNKS2PARP1GUSBPARP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0058822-A1 Method to alter or control the development and/or life cycle of various plant species AMERICAN CYANAMID COMPANY (US) 1982-09-01 EP claimed
EP-4583874-A1 MULTITARGET NUCLEAR RECEPTOR LIGANDS BASED ON 2-(4-(QUINOLIN-2-YLOXY)PHENOXY)PROPANOIC ACID AND 2-(4-(QUINOXALIN-2-YLOXY)PHENOXY)PROPANOIC ACID FOR THE TREATMENT OF METABOLIC AND LIVER DISEASES CHARLES UNIVERSITY, FACULTY OF PHARMACY IN HRADEC KRALOVE (CZ) 2025-07-16 EP disclosed
WO-2024132001-A1 MULTITARGET NUCLEAR RECEPTOR LIGANDS BASED ON 2-(4-(QUINOLIN-2-YLOXY)PHENOXY)PROPANOIC ACID AND 2-(4-(QUINOXALIN-2-YLOXY)PHENOXY)PROPANOIC ACID FOR THE TREATMENT OF METABOLIC AND LIVER DISEASES CHARLES UNIVERSITY, FACULTY OF PHARMACY IN HRADEC KRALOVE (CZ) 2024-06-27 WO disclosed
CN-115010671-B One-step synthesis method of 2-substituted quinazolinone 江苏大学 2023-10-10 CN disclosed
CN-115010671-A One-step synthesis method of 2-substituted quinazolinone 江苏大学 2022-09-06 CN disclosed
CN-106518789-B A method of synthesis Quinazol derivative 南京理工大学 2019-04-16 CN disclosed
CN-106518789-A Method for synthesis of quinazolinone derivative 南京理工大学 2017-03-22 CN disclosed
CN-106478525-A A kind of method of synthesis quinazolone 南京理工大学 2017-03-08 CN disclosed
US-20120059002-A1 NOVEL ANTI-INFLAMMATORY AGENTS HEPALINK (HONG KONG) LIMITED (HK) 2012-03-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120059002-A1 NOVEL ANTI-INFLAMMATORY AGENTS VCAM1, ICAM1, IL6 TNKS 723/4885TNKS2 1458/4885PARP1 901/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.